1
Total investments
0
Early stage
0
Mid stage
1
Late stage
2y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
FemTech III Fund Investor
2024
Portfolia is the most powerful community of women and men investing in the companies we want in the world.
Our collective investments are changing health, active aging & longevity, sustainability, education, and the overall venture capital landscape while also backing diversity.
Our currently open funds are Femtech III, focused on enhancing the wellness of all women, and advancing innovation in womens health; and Active Aging & Longevity II, focused on significant opportunities and challenges in aging well, as well as those focused on new strides and technologies in the field of longevity.
We drive change while creating wealth.
If youd like to join us, email investorrelations@portfolia.com, and our Investor Relations Team will contact you.
Experience · 6 entries
All (6)
Investments (1)
2025
Associate Vice President
Sep 2025
Baylor Genetics is a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, including Whole Genome Sequencing, Whole Exome Sequencing, and focused panels. Baylor Genetics combines rapid and comprehensive precision diagnostics options with the support of genetic counselors to help clinicians avoid a lengthy diagnostic odyssey for their patients, guide medical management, and ensure no patient with a genetic disorder gets left behind. Baylor Genetics’ testing menu covers family planning, pregnancy, neonatal and pediatric testing, oncology, and many other specialized testing options. Located in Houston’s Texas Medical Center, Baylor Genetics serves clients in 50 states.
2024
FemTech III Fund Investor
2024
Portfolia is the most powerful community of women and men investing in the companies we want in the world.
Our collective investments are changing health, active aging & longevity, sustainability, education, and the overall venture capital landscape while also backing diversity.
Our currently open funds are Femtech III, focused on enhancing the wellness of all women, and advancing innovation in womens health; and Active Aging & Longevity II, focused on significant opportunities and challenges in aging well, as well as those focused on new strides and technologies in the field of longevity.
We drive change while creating wealth.
If youd like to join us, email investorrelations@portfolia.com, and our Investor Relations Team will contact you.
2022
Founding Limited Partner (LP)
2022
The Neythri Futures Fund is a historic first fund with a mission to increase the diversity quotient in the venture capital ecosystem. The Neythri Futures Fund positions South Asian women front and center as key investors and stakeholders and offers an opportunity to amplify their influence and catalyze innovation.
The Fund offers a distinct and differentiated advantage to the startups it invests in - access to the diverse, talent network of its LP base that is composed of senior executives, operators, investors, and board members who are committed to the success of these companies. The Neythri Futures Fund will invest in tech-enabled, venture scale startups led by diverse teams.
2019
Director, Global Product Strategy and Product Management (Oncotype Dx Portfolio)
2019
At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.
Were hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Lets take on cancer, together.
2018
Associate Director, Product Management
2018
Founded with a purpose to bring the full power of a lab to those providing care, Talis Bio is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
While timely diagnosis of infectious diseases is critically important to enable effective treatment, testing is primarily performed in centralized laboratories, which require specimens to be shipped for processing, delaying the return of results by days. Point-of-care testing solves this problem by empowering healthcare providers to generate lab quality results without the wait. From the doctor’s office to remote care settings, we are re-defining the treatment of infectious diseases.
The Talis One™ point-of-care system is designed to deliver fast, accurate, lab-quality molecular diagnostic testing in a variety of health care settings. Talis Bio strives to deliver results from sample to answer in less than 30 minutes.
To achieve our purpose, we focus on three things:
1. Putting customers and patients first
2. Making Talis Bio a great place to work
3. Living our values to Dream Big, Share Our Screens, Serve Others, Bring Our “A” Game, and Build Trust
Show all 6 entries ↓
